Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0793
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2637
    +0.0015 (+0.12%)
     
  • USD/JPY

    151.2140
    -0.1580 (-0.10%)
     
  • Bitcoin USD

    69,835.78
    -1,351.55 (-1.90%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

RedHill Biopharma's Talicia Recommended For H. Pylori Infection

  • RedHill Biopharma Ltd (NASDAQ: RDHL) has announced the publication of a new study revealing concerning rates of widespread, physician-directed prescribing of clarithromycin-based regimens for H. pylori infection despite rising rates of antibiotic resistance and prior patient macrolide use.

  • The data were published in the journal Digestive Diseases and Sciences.

  • The publication notes that over 80% of all prescriptions for H. pylori infection are clarithromycin-based therapies, despite ACG recommendations to avoid clarithromycin triple therapy in patients with any prior macrolide use or in regions where the resistance rate is known to be 15% or above.

  • "Such failure rates and resistance have not been seen with Talicia," said Dr. Colin W. Howden, Chief of the Division of Gastroenterology, University of Tennessee Health Science Center.

  • Since it does not contain clarithromycin, Talicia can be prescribed first-line without having to be concerned about local clarithromycin resistance, prior macrolide use, or patient CYP2C19 status," Dr. Colin added.

  • Talicia is a fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole).

  • In November 2019, Talicia was approved by the FDA to treat H. pylori infection in adults.

  • Related Link: RedHill Biopharma's Talicia For Bacterial Infections Shows Efficacy Irrespective of Patient BMI.

  • Price Action: RDHL shares are up 1.25% at $3.23 during the market session on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement